Trevi Therapeutics (NASDAQ:TRVI) Raised to “Strong-Buy” at Leerink Partnrs

Leerink Partnrs upgraded shares of Trevi Therapeutics (NASDAQ:TRVI) to a strong-buy rating in a report published on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q3 2024 earnings at ($0.12) EPS, Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.44) EPS and FY2026 earnings at ($0.45) EPS.

Several other analysts have also issued reports on TRVI. Rodman & Renshaw initiated coverage on Trevi Therapeutics in a research note on Thursday, June 13th. They issued a buy rating and a $7.00 price objective on the stock. Leerink Partners assumed coverage on Trevi Therapeutics in a report on Monday. They set an outperform rating and a $7.00 price target for the company. HC Wainwright started coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set a buy rating and a $6.00 price objective for the company. Raymond James started coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They set an outperform rating and a $9.00 target price for the company. Finally, EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a strong-buy rating in a research note on Monday, August 19th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Buy and a consensus price target of $7.67.

Trevi Therapeutics Stock Up 4.8 %

NASDAQ:TRVI opened at $3.30 on Monday. Trevi Therapeutics has a twelve month low of $0.97 and a twelve month high of $4.00. The firm has a market capitalization of $239.55 million, a price-to-earnings ratio of -9.71 and a beta of 0.96. The stock’s 50 day moving average price is $2.89 and its two-hundred day moving average price is $2.88.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same quarter in the prior year, the company earned ($0.07) EPS. As a group, analysts anticipate that Trevi Therapeutics will post -0.47 earnings per share for the current year.

Insider Activity at Trevi Therapeutics

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the transaction, the chief executive officer now owns 213,313 shares in the company, valued at approximately $644,205.26. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the transaction, the insider now directly owns 220,315 shares of the company’s stock, valued at approximately $608,069.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jennifer L. Good sold 10,981 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at approximately $644,205.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,355 shares of company stock worth $116,663. Corporate insiders own 24.37% of the company’s stock.

Hedge Funds Weigh In On Trevi Therapeutics

Institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD bought a new stake in shares of Trevi Therapeutics during the 1st quarter valued at approximately $47,000. Hsbc Holdings PLC bought a new stake in shares of Trevi Therapeutics during the second quarter worth $61,000. The Manufacturers Life Insurance Company lifted its stake in shares of Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after acquiring an additional 11,450 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Trevi Therapeutics by 17.1% during the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after acquiring an additional 7,902 shares in the last quarter. Finally, Oppenheimer & Co. Inc. bought a new stake in Trevi Therapeutics during the 1st quarter worth $208,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.